| Ticker Details |
Medpace Holdings, Inc.
Medpace Holdings Inc is a clinical contract research organisation. It is engaged in providing scientifically-driven clinical research-based drug and medical device development services to the biotechnology, pharmaceutical and medical device industries.
|
| IPO Date: |
August 11, 2016 |
| Sector: |
Healthcare |
| Industry: |
Medical Diagnostics and Research |
| Market Cap: |
$12.36B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$2.95 | 1.64%
|
| Avg Daily Range (30 D): |
$7.35 | 1.67%
|
| Avg Daily Range (90 D): |
$8.71 | 1.83%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.28M |
| Avg Daily Volume (30 D): |
.38M |
| Avg Daily Volume (90 D): |
.32M |
| Trade Size |
| Avg Trade Size (Sh.): |
43 |
| Avg Trade Size (Sh.) (30 D): |
23 |
| Avg Trade Size (Sh.) (90 D): |
22 |
| Institutional Trades |
| Total Institutional Trades: |
3,247 |
| Avg Institutional Trade: |
$6.89M |
| Avg Institutional Trade (30 D): |
$14.87M |
| Avg Institutional Trade (90 D): |
$18.89M |
| Avg Institutional Trade Volume: |
.04M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$8.43M |
| Avg Closing Trade (30 D): |
$19.79M |
| Avg Closing Trade (90 D): |
$22.84M |
| Avg Closing Volume: |
41.26K |
|
|
| News |
May 22, 2026 @ 4:00 PM
Bronstein, Gewirtz & Grossman LLC Urges Medpace Ho...
Source: Bronstein, Gewirtz & Grossman Llc
|
May 20, 2026 @ 10:00 PM
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages ...
Source: Rosen Law Firm
|
May 19, 2026 @ 12:48 AM
ROSEN, LEADING INVESTOR COUNSEL, Encourages Medpac...
Source: Rosen Law Firm
|
May 19, 2026 @ 12:12 AM
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regenc...
Source: Rosen Law Firm
|
May 15, 2026 @ 5:40 PM
Deadline Alert: Medpace Holdings, Inc. (MEDP) Shar...
Source: Glancy Prongay Wolke & Rotter Llp
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$16.22
|
$4.35
|
$4.76
|
|
Diluted EPS
|
$15.88
|
$4.28
|
$4.64
|
|
Revenue
|
$2.68B
|
$706.6M
|
$708.45M
|
|
Gross Profit
|
$778.59M
|
$196.33M
|
$205.32M
|
|
Net Income / Loss
|
$460.4M
|
$123.87M
|
$135.13M
|
|
Operating Income / Loss
|
$562.92M
|
$141.5M
|
$153.27M
|
|
Cost of Revenue
|
$1.9B
|
$510.28M
|
$503.13M
|
|
Net Cash Flow
|
$211.25M
|
$155.63M
|
$211.7M
|
|
PE Ratio
|
|
|
|
|
|
|
